290 related articles for article (PubMed ID: 33554732)
21. Functional characterization and development of novel human kinase insert domain receptor chimeric antigen receptor T-cells for immunotherapy of non-small cell lung cancer.
Zhong M; Chalbatani GM; Deng M; Li Q; Gharagouzloo E; Hamblin MR; Suarez ER; Hu L; Wang D
Eur J Pharm Sci; 2023 Jan; 180():106331. PubMed ID: 36384203
[TBL] [Abstract][Full Text] [Related]
22. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
23. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
24. Coexpression of
Xu T; Wang C; Chen X; Bai J; Wang E; Sun M
Immunotherapy; 2022 Dec; 14(18):1457-1466. PubMed ID: 36597720
[TBL] [Abstract][Full Text] [Related]
25. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
Front Immunol; 2020; 11():573823. PubMed ID: 33072116
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
27. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
28. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
[TBL] [Abstract][Full Text] [Related]
29. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
Hudecek M; Sommermeyer D; Kosasih PL; Silva-Benedict A; Liu L; Rader C; Jensen MC; Riddell SR
Cancer Immunol Res; 2015 Feb; 3(2):125-35. PubMed ID: 25212991
[TBL] [Abstract][Full Text] [Related]
30. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
[TBL] [Abstract][Full Text] [Related]
31. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.
Fujiwara K; Masutani M; Tachibana M; Okada N
Biochem Biophys Res Commun; 2020 Jun; 527(2):350-357. PubMed ID: 32216966
[TBL] [Abstract][Full Text] [Related]
32. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
[TBL] [Abstract][Full Text] [Related]
34. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
[TBL] [Abstract][Full Text] [Related]
35. Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling.
Landoni E; Fucá G; Wang J; Chirasani VR; Yao Z; Dukhovlinova E; Ferrone S; Savoldo B; Hong LK; Shou P; Musio S; Padelli F; Finocchiaro G; Droste M; Kuhlman B; Shamshiev A; Pellegatta S; Dokholyan NV; Dotti G
Cancer Immunol Res; 2021 Apr; 9(4):441-453. PubMed ID: 33547226
[TBL] [Abstract][Full Text] [Related]
36. Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation.
McComb S; Nguyen T; Shepherd A; Henry KA; Bloemberg D; Marcil A; Maclean S; Zafer A; Gilbert R; Gadoury C; Pon RA; Sulea T; Zhu Q; Weeratna RD
Front Immunol; 2022; 13():864868. PubMed ID: 35935988
[TBL] [Abstract][Full Text] [Related]
37. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
38. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
39. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
40. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
